Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

NCT06916494 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Muscle Invasive Bladder Cancer

Interventions

DRUG: Rutin
DRUG: Gemcitabine, Cisplatin
DRUG: Tislelizumab

Sponsor

First Affiliated Hospital of Chongqing Medical University